The Experts below are selected from a list of 381684 Experts worldwide ranked by ideXlab platform

Don C Bienfang - One of the best experts on this subject based on the ideXlab platform.

  • Interleukin 2 and regulatory t cells in graft versus host disease
    The New England Journal of Medicine, 2011
    Co-Authors: John Koreth, Kenichi Matsuoka, Haesook T Kim, Sean Mcdonough, Bhavjot Bindra, Edwin P Alyea, Philippe Armand, Corey Cutler, Nathaniel S Treister, Don C Bienfang
    Abstract:

    Background Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose Interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. Methods In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous Interleukin-2 (0.3×106, 1×106, or 3×106 IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive Interleukin-2 for an extended period. Results A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of Interleukin-2 was 1×106 IU per square meter. The highest dose level induced unacc...

Agamemnon A Epenetos - One of the best experts on this subject based on the ideXlab platform.

  • a recombinant single chain antibody Interleukin 2 fusion protein
    British Journal of Cancer, 1993
    Co-Authors: Philip Savage, A K So, Robert A Spooner, Agamemnon A Epenetos
    Abstract:

    Recombinant Interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell carcinoma. However its use can be limited by severe systemic toxicity. Targeting rIL-2 to the tumour should improve the anti-tumour immune response and decrease the systemic toxicity. With this aim we have employed recombinant DNA techniques to construct a single chain antibody Interleukin-2 fusion protein (SCA-IL-2). The protein used in this model system comprises the variable domains of the anti-lysozyme antibody D1.3 fused to human IL-2. It has been expressed by secretion from Escherichia coli and the purified product possesses antigen binding specificity and retains the immunostimulatory activities of rIL-2. This approach can be taken to generate SCA-IL-2 proteins that bind to appropriate cellular antigens. In vivo administration of a tumour binding SCA-IL-2 should result in a localised high concentration of IL-2 in tumour tissues, maximising the anti-tumour immune response, whilst keeping systemic side effects to a minimum.

  • a recombinant single chain antibody Interleukin 2 fusion protein
    International Hammersmith meeting, 1993
    Co-Authors: Philip Savage, A K So, Robert A Spooner, Agamemnon A Epenetos
    Abstract:

    Recombinant Interleukin-2 (rIL-2) therapy has been shown to be of value in the treatment of some cases of melanoma and renal cell carcinoma. However, its use can be limited by severe systemic toxicity. Targeting rIL-2 to the tumor should improve the antitumor immune response and decrease the systemic toxicity. With this aim, we have employed recombinant DNA techniques to construct a single-chain antibody Interleukin-2 fusion protein (SCA-IL-2).

Richard P Macdermott - One of the best experts on this subject based on the ideXlab platform.

  • Increased in vitro release of soluble Interleukin 2 receptor by colonic lamina propria mononuclear cells in inflammatory bowel disease.
    Gut, 1992
    Co-Authors: Stefan Schreiber, Andreas Raedler, A R Conn, J L Rombeau, Richard P Macdermott
    Abstract:

    Increased concentrations of the soluble form of the Interleukin 2 receptor have been observed in the sera of Crohn's disease and ulcerative colitis patients. In this study we have observed the spontaneous release of soluble Interleukin 2 receptor by unstimulated, isolated normal and inflammatory bowel disease colonic lamina propria mononuclear cells. Lamina propria mononuclear cells from Crohn's disease patients (median = 204 U/ml (interquartile range 126-396, n 17) secreted significantly (p less than 0.01) more soluble Interleukin 2 receptor than normal controls (median = 124.5 U/ml (108-131), n 12). No statistically significant differences were seen between ulcerative colitis (median = 135 U/ml (92-196), n 20) and normal controls. Moreover, significantly (p less than 0.01) increased amounts of soluble Interleukin 2 receptor were secreted by colonic diverticulitis lamina propria mononuclear cells (median = 259 U/ml (149-282), n 15) which were used as disease specificity controls. Time course experiments showed that the majority of soluble Interleukin 2 receptor was released by isolated lamina propria mononuclear cells in the first six days of culture. Upon stimulation with pokeweed mitogen, Crohn's disease (median = 2258 U/ml (1435-3584), n 14), normal control (median = 2622 U/ml (2030-3180), n 14) and diverticulitis lamina propria mononuclear cells (median = 2745 U/ml (1733-3192), n 10) reached similar maximal soluble Interleukin 2 receptor secretion levels, while ulcerative colitis lamina propria mononuclear cells secreted significantly (p less than 0.005) less soluble Interleukin 2 receptor (median = 912 U/ml (494-1259), n 17). These results suggest that enhanced shedding/secretion of soluble Interleukin 2 receptor by intestinal lymphocytes may account in part for increased serum soluble Interleukin 2 receptor concentrations during chronic intestinal inflammatory reactions.

Wen Qiao - One of the best experts on this subject based on the ideXlab platform.

  • effects of selenium on peripheral blood mononuclear cell membrane fluidity Interleukin 2 production and Interleukin 2 receptor expression in patients with chronic hepatitis
    World Journal of Gastroenterology, 2004
    Co-Authors: Xinming Chang, Wen Qiao
    Abstract:

    AIM: To study the effect of selenium on peripheral blood mononuclear cell (PBMC) membrane fluidity and immune function in patients with chronic hepatitis. METHODS: PBMCs were pretreated with selenium (1.156 × 10-7 mol/L) for 6 h in vitro or extracted directly from patients after administration of selenium-yeast continuously for 8-12 wk (200 μg/d), and then exposed to Con-A for 48 h. The membrane fluidity, Interleukin-2 (IL-2) production and Interleukin-2 receptor (IL-2R) expression in PBMCs and malondialdehyde (MDA) concentration in medium and lipid peroxide (LPO) in plasma were determined. RESULTS: The PBMC membrane fluidity, IL-2 production and IL-2R expression in patients with chronic hepatitis were significantly lower than those in healthy blood donators (particle adhesive degree R, 0.17 ± 0.01 vs 0.14 ± 0.01, P < 0.01; IL-2, 40.26 ± 9.55 vs 72.96 ± 11.36, P < 0.01; IL-2R, 31.05 ± 5.09 vs 60.58 ± 10.56, P < 0.01), and the MDA concentration in medium in patients with chronic hepatitis was significantly higher than that in healthy blood donators (1.44 ± 0.08 vs 0.93 ± 0.08, P < 0.01). Both in vitro and in vivo administration of selenium could reverse the above parameters. CONCLUSION: Supplement of selenium can suppress lipid peroxidation, and improve PBMC membrane fluidity and immune function in patients with chronic hepatitis.

Ricardo Pasquini - One of the best experts on this subject based on the ideXlab platform.